Nexavar (Sorafenib Tosylate) Patent Expiration, LOE Window & CMS Spending

Nexavar (Sorafenib Tosylate) by Bayer: FDA Orange Book core substance LOE 2027-12-24 (last listed 2028-09-10), 5 AB generics, $7.7M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBayer
FDA Application & PathwayN021923 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2027-12-24
Last Listed Patent or Exclusivity Date2028-09-10
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$7.7M
2024 Medicare Part D Spend$4.3M
2024 Medicaid Spend$3.4M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 22.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.